Vasoactive Intestinal Peptide-Receptor Imaging for the Localization of Intestinal Adenocarcinomas and Endocrine Tumors

Virgolini, Irene; Raderer, Markus; Kurtaran, Amir; Angelberger, P.; Banyai, S; Yang, Quanxin; Li, S; Banyai, Martin; Pidlich, Johann; Niederle, B; Scheithauer, Werner; Valent, Peter

doi:10.1097/00019616-199503000-00021

Cited by 37 publications

(54 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In support of this hypothesis is the earlier report of elevated plasma and tissue levels of VIP in many types of tumours (Said & Faloona, 1975). Furthermore, VIP receptors are present in a human pancreatic adenocarcinoma cell line (Estival et al, 1983) and localized in patients with gastrointestinal tumours (Virgolini et al, 1994). Our findings suggest that, in these clinical situations, VIP might contribute to tumour angiogenesis and subsequent metastasis.…”

Section: Discussionsupporting

confidence: 87%

Comparative studies of the angiogenic activity of vasoactive intestinal peptide, endothelins‐1 and −3 and angiotensin II in a rat sponge model

Hiley

Fan

1996

British J Pharmacology

View full text Add to dashboard Cite

The angiogenic activity of four vasoactive peptides with a range of vasodilator and vasoconstrictor properties, i.e. vasoactive intestinal peptide (VIP), endothelin‐1, endothelin‐3 and angiotensin II, were investigated in a rat sponge model. Neovascularization was assessed by the 133Xe clearance technique and confirmed by histological studies. Daily doses of the vasodilator peptide, VIP (1000 pmol), caused intense neovascularization, but a lower dose (10 pmol) produced no apparent effect. However, the lower dose of VIP, when given with a subthreshold dose of interleukin‐1α (0.3 pmol), produced an angiogenic response similar to that seen with the higher dose of VIP. The neovascular response induced by co‐administration of VIP and interleukin‐1α was inhibited by simultaneous administration of 100 pmol VIP (10–28), a specific VIP receptor antagonist. In contrast, daily doses of 10, 100 or 1000 pmol endothelin‐3 (a mixed vasoconstrictor and vasodilator with more marked vasodilator activity) or of 100 or 1000 pmol endothelin‐1 (also with mixed activity but with much more pronounced vasoconstrictor response) produced no apparent effect on sponge‐induced angiogenesis. The vasoconstrictor peptide, angiotensin II, in daily doses of 1000 pmol, caused an intense neovascularization like VIP but lower doses of angiotensin II (10 or 100 pmol) produced no apparent effect. The lowest dose of angiotensin II (10 pmol) when administered with the subthreshold dose of interleukin‐1α (0.3 pmol) had no effect on the basal neovascular response in the sponges. The angiotensin II‐induced neovascular response was inhibited by co‐administration of 100 nmol of the specific AT1 receptor antagonist, losartan, but not by the AT2 receptor antagonist, PD 123319. These data show that VIP and angiotensin II possess angiogenic activity. However, endothelin‐1 and endothelin‐3 had no activity at the doses used. Thus the angiogenic response is not related to local vasoconstriction or vasodilatation in the sponges. The blockade of VIP‐ and angiotensin II‐induced angiogenesis at the receptor level suggests that receptor modulation could provide a strategy for the management of angiogenic diseases.

show abstract

Section: Discussionsupporting

confidence: 87%

Comparative studies of the angiogenic activity of vasoactive intestinal peptide, endothelins‐1 and −3 and angiotensin II in a rat sponge model

Hiley

Fan

1996

British J Pharmacology

View full text Add to dashboard Cite

show abstract

“…radiograph, computerized tomography (CT), ultrasound] are clinically useful, small tumours may escape detection. Unlike other approaches, including the use of radiolabelled monoclonal antibodies for diagnostic purpose, SST receptor scintigraphy ([ 111 In]-DTPA-D-Phe 1 -octreotide) was not found to be useful in patients with intestinal adenocarcinomas [17,23]. This is most probably because of the lack of high-affinity binding to SSTR3, which is the most important SSTR subtype receptor expressed in adenocarcinomas (Fig.…”

Section: Imaging Of Intestinal Adenocarcinomas (Gastric Colorectal Amentioning

confidence: 97%

“…Most importantly, the biological activity of [ 123 I]-VIP and unlabelled VIP is identical as routinely determined by the ability to enhance intracellular cAMP, tyrosine kinase activity as well as DNA de novo synthesis in terms of [ 3 H]-thymidine uptake [20]. [23].…”

Section: Vip and Sst Cross-compete For Cellular Binding Sitesmentioning

confidence: 99%

“…Furthermore, the demonstration of the SSTR subtype 3 to be the receptor site of this interaction [21] and the coexpression of binding sites for VIP and SST on tumour cells [20,22] support the significant role of the VIP/SST peptide receptors for tumour patients. Consequent clinical studies have used radioiodinated VIP for cancer detection [23][24][25]. This scintigraphy is clinically useful to localize small adenocarcinomas and endocrine tumours of the gastrointestinal tract [23].…”

Section: Introductionmentioning

confidence: 99%

“…Consequent clinical studies have used radioiodinated VIP for cancer detection [23][24][25]. This scintigraphy is clinically useful to localize small adenocarcinomas and endocrine tumours of the gastrointestinal tract [23]. As with SST receptor scintigraphy, the major clinical impact of the 'VIP receptor scintigraphy' is demonstrated by a change in clinical management in roughly 10% of patients, based on scanning results.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Mack Forster Award Lecture Receptor nuclear medicine: vasointestinal peptide and somatostatin receptor scintigraphy for diagnosis and treatment of tumour patients

Virgolini

1997

Eur J Clin Investigation

View full text Add to dashboard Cite

show abstract

Type 1 vasoactive intestinal peptide receptor expression in PC3/AR cells is evidence of prostate epithelial differentiation

2000

View full text Add to dashboard Cite

Vasoactive Intestinal Peptide-Receptor Imaging for the Localization of Intestinal Adenocarcinomas and Endocrine Tumors

Cited by 37 publications

References 0 publications

Comparative studies of the angiogenic activity of vasoactive intestinal peptide, endothelins‐1 and −3 and angiotensin II in a rat sponge model

Comparative studies of the angiogenic activity of vasoactive intestinal peptide, endothelins‐1 and −3 and angiotensin II in a rat sponge model

Mack Forster Award Lecture Receptor nuclear medicine: vasointestinal peptide and somatostatin receptor scintigraphy for diagnosis and treatment of tumour patients

Type 1 vasoactive intestinal peptide receptor expression in PC3/AR cells is evidence of prostate epithelial differentiation

Contact Info

Product

Resources

About